QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:BCAB

BioAtla - BCAB Stock Forecast, Price & News

$3.68
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.62
$3.77
50-Day Range
$3.18
$11.01
52-Week Range
$2.01
$12.15
Volume
230,776 shs
Average Volume
1.50 million shs
Market Capitalization
$138.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50

BioAtla MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
375.5% Upside
$17.50 Price Target
Short Interest
Healthy
8.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of BioAtla in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$47,361 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.96) to ($2.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

93rd out of 1,055 stocks

Biological Products, Except Diagnostic Industry

19th out of 170 stocks


BCAB stock logo

About BioAtla (NASDAQ:BCAB) Stock

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
BioAtla: Back From The Dead (NASDAQ:BCAB) - Seeking Alpha
Bioatla (BCAB) Investor Presentation - Slideshow
See More Headlines
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Company Calendar

Last Earnings
11/04/2022
Today
1/27/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+375.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-95,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$5.65 per share

Miscellaneous

Free Float
32,041,000
Market Cap
$138.39 million
Optionable
Not Optionable
Beta
0.65

Key Executives

  • Dr. Jay M. Short Ph.D. (Age 65)
    Co-Founder, CEO & Chairman
    Comp: $1.02M
  • Mr. Scott Andrew SmithMr. Scott Andrew Smith (Age 61)
    Pres & Director
    Comp: $798.89k
  • Mr. Richard A. WaldronMr. Richard A. Waldron (Age 69)
    Chief Financial Officer
    Comp: $593.51k
  • Dr. Eric L. Sievers M.D. (Age 59)
    Chief Medical Officer
    Comp: $552.62k
  • Mr. Christian VasquezMr. Christian Vasquez (Age 48)
    VP of Fin., Corp. Controller & Sec.
    Comp: $345.88k
  • Mr. Philippe Martin (Age 47)
    Chief Clinical Devel. & Operations
  • Lisa M. Pelton
    Accounting Mang.
  • Ms. Susie Melody
    Sr. VP of HR
  • Dr. Cathy Chang Ph.D.
    Sr. VP of R&D
  • Ms. Monica Sullivan
    Sr. VP of Intellectual Property & Contracts













BCAB Stock - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings
or view top-rated stocks.

What is BioAtla's stock price forecast for 2023?

4 equities research analysts have issued 12-month price objectives for BioAtla's shares. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 369.2% from the stock's current price.
View analysts price targets for BCAB
or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 at the beginning of 2023. Since then, BCAB stock has decreased by 54.8% and is now trading at $3.73.
View the best growth stocks for 2023 here
.

Are investors shorting BioAtla?

BioAtla saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,250,000 shares, a decrease of 21.9% from the December 31st total of 4,160,000 shares. Based on an average trading volume of 880,600 shares, the short-interest ratio is presently 3.7 days.
View BioAtla's Short Interest
.

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCAB earnings forecast
.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) posted its earnings results on Friday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.08.

When did BioAtla IPO?

(BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $3.73.

How much money does BioAtla make?

BioAtla (NASDAQ:BCAB) has a market capitalization of $140.27 million and generates $250,000.00 in revenue each year. The company earns $-95,400,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How can I contact BioAtla?

The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com.

This page (NASDAQ:BCAB) was last updated on 1/27/2023 by MarketBeat.com Staff